Virios Therapeutics Announces Second Quarter 2024 Financial Results
August 08, 2024 09:15 ET
|
Virios Therapeutics
- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the Bateman...
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
August 01, 2024 09:41 ET
|
Virios Therapeutics
ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:45 ET
|
Virios Therapeutics
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call...
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
May 02, 2024 09:15 ET
|
Virios Therapeutics
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
February 29, 2024 09:15 ET
|
Virios Therapeutics
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
January 22, 2024 09:00 ET
|
Virios Therapeutics
- Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 -- Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 - ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios...
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023 07:05 ET
|
Virios Therapeutics
- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on...